[Therapeutic procedures in gastroesophageal reflux disease].
The medical therapy of reflux esophagitis consists of modifications of the patients's lifestyle and antacids, alginic acid or both (phase I). Phase II medications include drugs that suppress acid/peptic activity (antacid/alginate, H2-receptor blockers, cimetidine, ranitidine, famotidine), drugs that enhance motility (metoclopramide, domperidone) and drugs that coat and increase mucosal protection (sucralfate). Combinations of H2-receptor blockers and motility stimulating drugs have not been very effective. Overall the results of medical therapy of reflux esophagitis are suboptimal.
D000464:Alginates / Q000627:therapeutic use; D000536:Aluminum Hydroxide / Q000627:therapeutic use; D000863:Antacids / Q000627:therapeutic use; D001639:Bicarbonates / Q000627:therapeutic use; D003131:Combined Modality Therapy; D004106:Dilatation; D004294:Domperidone / Q000627:therapeutic use; D004338:Drug Combinations / Q000627:therapeutic use; D004942:Esophagitis, Peptic / Q000188:drug therapy; D005764:Gastroesophageal Reflux / Q000188:drug therapy*; D006635:Histamine H2 Antagonists / Q000627:therapeutic use; D006801:Humans; D008787:Metoclopramide / Q000627:therapeutic use; D010528:Peristalsis / Q000187:drug effects; D012824:Silicic Acid / Q000627:therapeutic use; D017693:Sodium Bicarbonate; D013392:Sucralfate / Q000627:therapeutic use
D000464:Alginates; D000863:Antacids; D001639:Bicarbonates; D004338:Drug Combinations; D006635:Histamine H2 Antagonists; D012824:Silicic Acid; D013392:Sucralfate; D004294:Domperidone; D000536:Aluminum Hydroxide; C007829:alginate, aluminium hydroxide, magnesium trisilicate, sodium bicarbonate drug combination; D017693:Sodium Bicarbonate; D008787:Metoclopramide
Therapeutische Verfahren bei der gastroösophagealen Refluxkrankheit.